.
Cochlear Limited’s (ASX:COH) Nucleus Hybrid L24 Implant System is set to hit the US market after being approved by American authorities for commercial release.
The developer of implantable hearing solutions says its product has been given the go-ahead by the US Food and Drug Administration (FDA).
The authority’s green light for commercial release comes after its advisory panel gave its unanimous recommendation in November 2013.
Cochlear says the product is a first of its kind system designed for the treatment of adults with sever to profound sensorineural hearing loss in high-frequency sounds.
The Nucleus Hybrid is designed to deliver patients superior quality and clarity of sound even in the most difficult hearing situations.
Cochlear reported a net profit of $21 million in the first half of the 2014 financial year.
(20min delay)